Squares denote relative risks; horizontal lines represent 95% confidence intervals. Relative risks were adjusted, as planned, for age (<65 years), NYHA functional status III or IV, peripheral vascular disease, mitral surgery for insufficiency, serum creatinine values (continuous variable), low cardiac output syndrome as major cause of AKI, mechanical ventilation or cardiac support at randomization, systolic arterial blood pressure before surgery and at randomization (continuous variable). In the post-hoc analyses indicate with an asterisk, relative risks were adjusted for re-operative surgery, obesity, chronic lung disease, history of myocardial infarction, type of surgery, estimated Glomerular Filtration Rate calculated by means of the CKD-EPI (chronic kidney disease epidemiology collaboration) calculator (patients were stratified according to eGFR -estimated Glomerular Filtration Rate -categories defined by the KDIGO -kidney disease improving global outcome -guidelines to define CKD), quartiles of baseline serum creatinine levels. All p values>0.05 and test for interaction = 0.991 Centers using are sorted and numbered for ascending relative risks. Squares denote relative risks; horizontal lines represent 95% confidence intervals. Data on dose (μg/kg/min) and infusion duration (hours) are expressed as mean+standard deviation. P values refer to differences in renal replacement therapy between fenoldopam and placebo groups. All p values>0.05 and test for interaction = 0.906. Adjustments for multiple ad interim analyses. Assuming that 4 sequential tests were made using the O'Brien-Fleming spending function to determine the test boundaries, the higher than expected RRT incidence allowed to maintain >80% power to reject the hypothesis of a beneficial effect of fenoldopam and suggested to stop the trial for futility at the third interim analyses. In fact the probability of attaining a significant difference between groups by continuing the enrolment up to 1000 patients was considered sufficiently low. The patient is classified according to Serum Creatinine (SCr) and Urine Output (UO) separately and can fulfill criteria for classification stages through changes in each or both SCr and UO, whichever the worst. Changes are intended from baseline values (preoperative data in our study).The criteria for each stage are as follows: -stage R: SCr x1.5 (or GFR decrease>25%) or UO <0.5 ml/kg/h for 6 hours -stage I: SCr x2 (or GFR decrease>50%) or UO <0.5 ml/kg/h for 12 hours -stage F: SCr x3 (or GFR decrease>75%) or UO <0.3 ml/kg/h for 24 hours or anuria for 12 hours -stage L: Persistent AKI (need for RRT for >4 weeks) -stage E: End Stage Renal Disease (need for RRT for >3 months)Note that the F stage is achievable even if the increase in SCreat is under three times the baseline value as long as the new SCr is greater than 4.0 mg/dl with an acute increase of at least 0.5 mg/dl. The designation RIFLE-FC should be used in this case to denote "acute-on-chronic" disease. 
